Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370510 · ClinicalTrials.gov registry record · Phase 2
Translating Neuroprediction Into Precision Medicine Via Brain Priming
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03370510 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT03370510, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The present study examines the impact of oxytocin (OXT) and Pivotal Response Treatment (PRT) on the development of language, social, and play skills in young children with Autism Spectrum Disorder (ASD). The purpose of this study is to examine the impact of OXT as an enhancer of response to PRT. Participants will be randomly assigned to either an intranasal OXT group or a placebo group. Neither the research team nor the participants will know or choose which group the participant is assigned to. Children in both groups will participate in a 16-week trial of PRT. The trial will test the hypothesis that children with lower levels of activity in and functional connectivity among certain PRT-response brain regions will benefit more from the administration of OXT vs. placebo as an enhancer to a 16-week trial of PRT.
Interventions
- DRUG Placebo
- DRUG Oxytocin
- BEHAVIORAL Pivotal Response Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03370510
The ClinicalTrials.gov registry entry for NCT03370510 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03370510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03370510 about?
NCT03370510 is a clinical study titled "Translating Neuroprediction Into Precision Medicine Via Brain Priming". The present study examines the impact of oxytocin (OXT) and Pivotal Response Treatment (PRT) on the development of language, social, and play skills in young children with Autism Spectrum Disorder (ASD). The purpose of this study is to examine the impact of OXT as an enhancer of response to PRT. Par...
What is the current status of trial NCT03370510?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-12-07. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT03370510?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG), Pivotal Response Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT03370510?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.